Gene: PLCG2

5336
APLAID|FCAS3|PLC-IV|PLC-gamma-2
phospholipase C gamma 2
protein-coding
16q23.3
Ensembl:ENSG00000197943 MIM:600220 Vega:OTTHUMG00000176532 UniprotKB:P16885
NG_032019.2
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.723e-1 (AD)  2.005e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs4312298chr16:81947571 (GRCh38.p7)T>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TRIM380.895
ADPRH0.889
LPAR60.886
CD370.88
RIPK30.877
MYO1F0.876
CD330.875
MFNG0.873
TNFAIP80.872
APOBEC3C0.87

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASPDH-0.448
HAS1-0.421
MYADML2-0.42
ZNF835-0.416
CYP46A1-0.415
HAGHL-0.413
C9orf24-0.412
FBLL1-0.412
KCNIP3-0.411
TMEM179-0.41

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of PLCG2 mRNA19933214
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of PLCG2 mRNA"19114083
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCG2 mRNA"27188386
C0652504-hydroxy-equilenin4-hydroxy-equilenin results in decreased expression of PLCG2 mRNA15135645
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCG2 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of PLCG2 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 affects the expression of PLCG2 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of PLCG2 mRNA22100608|2715375
C412373AG 1879AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]25980585
D000643Ammonium ChlorideAmmonium Chloride affects the expression of PLCG2 mRNA16483693
C006632arsenic trioxidearsenic trioxide results in decreased phosphorylation of PLCG2 protein20129490
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased expression of PLCG2 mRNA"23634900|2535159
D001564Benzo(a)pyreneBenzo(a)pyrene metabolite results in decreased expression of PLCG2 mRNA26314263
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PLCG2 mRNA20064835
C006780bisphenol Abisphenol A affects the expression of PLCG2 mRNA21786754
C006780bisphenol Abisphenol A results in increased expression of PLCG2 mRNA29275510
C006780bisphenol Abisphenol A results in decreased expression of PLCG2 mRNA26063408
C006780bisphenol Abisphenol A results in decreased methylation of PLCG2 promoter27312807
C006780bisphenol Abisphenol A results in decreased expression of PLCG2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of PLCG2 gene28505145
C005961bis(tri-n-butyltin)oxidebis(tri-n-butyltin)oxide results in decreased expression of PLCG2 mRNA26314263
C584509C646 compoundC646 compound results in increased expression of PLCG2 mRNA26191083
D002118CalciumCalcium results in increased activity of PLCG2 protein25903139
D002118CalciumCalcium results in increased activity of PLCG2 protein mutant form25903139
D002118Calcium[Calcium results in increased activity of PLCG2 protein mutant form] which results in increased chemical synthesis of Inositol Phosphates25903139
D002118Calcium[Calcium results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates25903139
D002118CalciumCalcium promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]27542411
D002118CalciumCalcium promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]27542411
D000074262Canola OilCanola Oil metabolite results in decreased expression of PLCG2 mRNA27363782
D000074262Canola OilStarch analog inhibits the reaction [Canola Oil metabolite results in decreased expression of PLCG2 mRNA]27363782
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of PLCG2 mRNA17484886
C018021cobaltous chloridecobaltous chloride results in decreased expression of PLCG2 mRNA26314263
D003471CuprizoneCuprizone results in increased expression of PLCG2 mRNA26577399
C014347decitabinedecitabine affects the expression of PLCG2 mRNA23300844
D003687DehydroepiandrosteroneDehydroepiandrosterone results in increased expression of PLCG2 mRNA16940010
D002945CisplatinCisplatin affects the expression of PLCG2 mRNA23300844
C506907EHT 1864EHT 1864 inhibits the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]27542411
C118739entinostatentinostat results in increased expression of PLCG2 mRNA27188386
D000431EthanolEthanol results in increased expression of PLCG2 mRNA20655511
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of PLCG2 mRNA17942748
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PLCG2 mRNA17942748
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of PLCG2 gene16724327
C056516exemestaneexemestane results in increased expression of PLCG2 mRNA17254854
D004397FonofosFonofos results in increased methylation of PLCG2 promoter22847954
D009240N-Formylmethionine Leucyl-PhenylalanineAG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]25980585
D009240N-Formylmethionine Leucyl-Phenylalaninehonokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]25980585
D009240N-Formylmethionine Leucyl-PhenylalanineN-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein25980585
C069837fullerene C60fullerene C60 results in increased expression of PLCG2 mRNA19167457
D016244Guanosine 5'-O-(3-Thiotriphosphate)[Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]27542411
D016244Guanosine 5'-O-(3-Thiotriphosphate)[Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]27542411
D016244Guanosine 5'-O-(3-Thiotriphosphate)PLCG2 protein mutant form results in decreased susceptibility to [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)]25903139
D016244Guanosine 5'-O-(3-Thiotriphosphate)[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein25903139
D016244Guanosine 5'-O-(3-Thiotriphosphate)[[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates25903139
C005499honokiolhonokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]25980585
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of PLCG2 mRNA26846883
D006861Hydrogen PeroxideHydrogen Peroxide results in increased phosphorylation of PLCG2 protein25903139
D006861Hydrogen PeroxideHydrogen Peroxide results in increased phosphorylation of PLCG2 protein mutant form25903139
C492448ICG 001ICG 001 results in increased expression of PLCG2 mRNA26191083
D007295Inositol Phosphates[Calcium results in increased activity of PLCG2 protein mutant form] which results in increased chemical synthesis of Inositol Phosphates25903139
D007295Inositol Phosphates[Calcium results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates25903139
D007295Inositol PhosphatesCalcium promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]27542411
D007295Inositol PhosphatesCalcium promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]27542411
D007295Inositol PhosphatesEGF protein promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]27542411
D007295Inositol PhosphatesEGF protein promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]27542411
D007295Inositol PhosphatesEHT 1864 inhibits the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]27542411
D007295Inositol Phosphates[Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]27542411
D007295Inositol Phosphates[Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]27542411
D007295Inositol PhosphatesPLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates27542411
D007295Inositol Phosphates[PLCG2 protein mutant form results in increased susceptibility to RAC2 protein mutant form] which results in increased chemical synthesis of Inositol Phosphates27542411
D007295Inositol Phosphates[PLCG2 protein mutant form results in increased susceptibility to RAC2 protein] which results in increased chemical synthesis of Inositol Phosphates27542411
D007295Inositol PhosphatesPLCG2 protein results in increased chemical synthesis of Inositol Phosphates27542411
D007295Inositol Phosphates[RAC2 protein binds to and results in increased activity of PLCG2 protein mutant form] which results in increased chemical synthesis of Inositol Phosphates27542411
D007295Inositol Phosphates[[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates25903139
D007295Inositol Phosphates[RAC2 protein mutant form binds to and results in increased activity of PLCG2 protein mutant form] which results in increased chemical synthesis of Inositol Phosphates27542411
D007295Inositol Phosphates[RAC2 protein mutant form binds to and results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates27542411
D007295Inositol Phosphates[RAC2 protein mutant form results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates25903139
D007295Inositol Phosphates[VAV1 protein mutant form binds to and results in increased activity of PLCG2 protein mutant form] which results in increased chemical synthesis of Inositol Phosphates27542411
C544151jinfukangjinfukang results in increased expression of PLCG2 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound promotes the reaction [PCI 32765 results in decreased phosphorylation of PLCG2 protein]26254443
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased phosphorylation of PLCG2 protein26254443
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of PLCG2 mRNA24796395
C561695(+)-JQ1 compoundPCI 32765 promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of PLCG2 protein]26254443
D008748Methylcholanthrene[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PLCG2 mRNA23519560
C030957methylmercury IImethylmercury II results in decreased expression of PLCG2 mRNA26314263
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of PLCG2 mRNA"25620056
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of PLCG2 mRNA19812364
C028007nickel monoxidenickel monoxide results in increased expression of PLCG2 mRNA19167457
C029938nickel sulfatenickel sulfate results in increased expression of PLCG2 mRNA22714537
C025589ochratoxin Aochratoxin A metabolite results in decreased expression of PLCG2 mRNA26314263
C025589ochratoxin Aochratoxin A results in decreased expression of PLCG2 mRNA26314263
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of PLCG2 mRNA25729387
D010126OzoneOzone results in decreased expression of PLCG2 mRNA16330353
D010269ParaquatParaquat affects the expression of PLCG2 mRNA18198484
D010269ParaquatParaquat results in decreased expression of PLCG2 mRNA17077588
D010278ParathionParathion results in increased methylation of PLCG2 promoter22847954
C551803PCI 32765(+)-JQ1 compound promotes the reaction [PCI 32765 results in decreased phosphorylation of PLCG2 protein]26254443
C551803PCI 32765PCI 32765 promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of PLCG2 protein]26254443
C551803PCI 32765PCI 32765 results in decreased phosphorylation of PLCG2 protein26254443
C551803PCI 32765PLCG2 protein mutant form results in decreased susceptibility to PCI 3276527542411
D010634PhenobarbitalPhenobarbital results in decreased expression of PLCG2 mRNA16940010
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of PLCG2 mRNA19710929
C006253pirinixic acidpirinixic acid results in decreased expression of PLCG2 mRNA17426115
C006253pirinixic acidpirinixic acid results in increased expression of PLCG2 mRNA16940010
D010936Plant ExtractsPlant Extracts results in increased expression of PLCG2 mRNA23557933
D011441PropylthiouracilPropylthiouracil results in increased expression of PLCG2 mRNA24780913
C014175pyrazolo(3,4-d)pyrimidine"pyrazolo(3,4-d)pyrimidine analog affects the expression of PLCG2 mRNA"21152443
C059514resveratrolresveratrol inhibits the reaction [COL1A1 protein results in increased phosphorylation of PLCG2 protein]26482867
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of PLCG2 mRNA25895662
D019821SimvastatinSimvastatin results in increased expression of PLCG2 mRNA17428261
D012969Sodium FluorideSodium Fluoride results in decreased expression of PLCG2 mRNA21340527
C080613spiraeosidespiraeoside results in decreased phosphorylation of PLCG2 protein15613018
D013213StarchStarch analog inhibits the reaction [Canola Oil metabolite results in decreased expression of PLCG2 mRNA]27363782
C012568terbufosterbufos results in increased methylation of PLCG2 promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PLCG2 mRNA26377647
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PLCG2 mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of PLCG2 mRNA20159946
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PLCG2 mRNA19770486|1993321
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PLCG2 mRNA22298810
D013755Tetradecanoylphorbol Acetate[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PLCG2 mRNA23519560
C009495titanium dioxidetitanium dioxide results in increased expression of PLCG2 mRNA23557971
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of PLCG2 mRNA25729387
C032910triadimefontriadimefon results in decreased expression of PLCG2 mRNA26790661
C011559tributyltintributyltin results in decreased expression of PLCG2 mRNA26314263
C012589trichostatin Atrichostatin A results in increased expression of PLCG2 mRNA15901671
D014520UrethaneUrethane results in increased expression of PLCG2 mRNA28818685
D014635Valproic AcidValproic Acid results in increased expression of PLCG2 mRNA15901671
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCG2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of PLCG2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of PLCG2 mRNA23179753|2438349
D014638VanadatesVanadates results in decreased expression of PLCG2 mRNA22714537

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001784phosphotyrosine residue binding-IPI20624904  
GO:0004435phosphatidylinositol phospholipase C activity-IDA11606584  12181444  
GO:0004435phosphatidylinositol phospholipase C activity-TAS-  
GO:0004629phospholipase C activity-TAS-  
GO:0005515protein binding-IPI15644415  16273093  17474147  24642916  24658140  24728074  
25241761  25814554  
GO ID GO Term Qualifier Evidence PubMed
GO:0002092positive regulation of receptor internalization-IEA-  
GO:0002223stimulatory C-type lectin receptor signaling pathway-TAS-  
GO:0002316follicular B cell differentiation-IEA-  
GO:0006661phosphatidylinositol biosynthetic process-IDA11606584  12181444  
GO:0009395phospholipid catabolic process-IEA-  
GO:0010468regulation of gene expression-IEA-  
GO:0016055Wnt signaling pathway-TAS18784435  
GO:0019722calcium-mediated signaling-NAS11043765  
GO:0030168platelet activation-TAS-  
GO:0030183B cell differentiation-ISS-  
GO:0032237activation of store-operated calcium channel activity-IEA-  
GO:0032481positive regulation of type I interferon production-IEA-  
GO:0032496response to lipopolysaccharide-IEA-  
GO:0032959inositol trisphosphate biosynthetic process-IEA-  
GO:0038095Fc-epsilon receptor signaling pathway-TAS-  
GO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis-TAS-  
GO:0043069negative regulation of programmed cell death-IEA-  
GO:0043647inositol phosphate metabolic process-TAS-  
GO:0050852T cell receptor signaling pathway-ISS-  
GO:0050853B cell receptor signaling pathway-ISS-  
GO:0051209release of sequestered calcium ion into cytosol-IDA11606584  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-IDA11606584  
GO:0005886plasma membrane-TAS-  
GO:0070062extracellular exosome-HDA20458337  
KEGG ID KEGG Term
hsa00562Inositol phosphate metabolism
hsa01100Metabolic pathways
hsa04012ErbB signaling pathway
hsa04020Calcium signaling pathway
hsa04070Phosphatidylinositol signaling system
hsa04370VEGF signaling pathway
hsa04380Osteoclast differentiation
hsa04650Natural killer cell mediated cytotoxicity
hsa04662B cell receptor signaling pathway
hsa04664Fc epsilon RI signaling pathway
hsa04666Fc gamma R-mediated phagocytosis
hsa04670Leukocyte transendothelial migration
hsa04722Neurotrophin signaling pathway
hsa05110Vibrio cholerae infection
hsa05120Epithelial cell signaling in Helicobacter pylori infection
hsa05200Pathways in cancer
hsa05214Glioma
hsa05223Non-small cell lung cancer
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-114604GPVI-mediated activation cascadeTAS
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-1430728MetabolismTAS
R-HSA-1483249Inositol phosphate metabolismTAS
R-HSA-166016Toll Like Receptor 4 (TLR4) CascadeTAS
R-HSA-168249Innate Immune SystemTAS
R-HSA-168249Innate Immune SystemIEA
R-HSA-168256Immune SystemTAS
R-HSA-168256Immune SystemIEA
R-HSA-168898Toll-Like Receptors CascadesTAS
R-HSA-1855204Synthesis of IP3 and IP4 in the cytosolTAS
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisTAS
R-HSA-2029485Role of phospholipids in phagocytosisTAS
R-HSA-2172127DAP12 interactionsTAS
R-HSA-2424491DAP12 signalingTAS
R-HSA-2454202Fc epsilon receptor (FCERI) signalingTAS
R-HSA-2454202Fc epsilon receptor (FCERI) signalingIEA
R-HSA-2871796FCERI mediated MAPK activationTAS
R-HSA-2871809FCERI mediated Ca+2 mobilizationTAS
R-HSA-2871809FCERI mediated Ca+2 mobilizationIEA
R-HSA-5607764CLEC7A (Dectin-1) signalingIEA
R-HSA-5607764CLEC7A (Dectin-1) signalingTAS
R-HSA-5621480Dectin-2 familyTAS
R-HSA-5621480Dectin-2 familyIEA
R-HSA-5621481C-type lectin receptors (CLRs)IEA
R-HSA-5621481C-type lectin receptors (CLRs)TAS
R-HSA-76002Platelet activation, signaling and aggregationTAS
R-HSA-983695Antigen activates B Cell Receptor (BCR) leading to generation of second messengersTAS
R-HSA-983705Signaling by the B Cell Receptor (BCR)TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal